Skip to main navigation Skip to search Skip to main content

A multicenter study of a predictive model for pathological complete response after neoadjuvant therapy in breast cancer using multimodal digital biomarkers

  • Zixuan Yang
  • , Jie He
  • , Taolang Li
  • , Changdong Liu
  • , Yongsheng Wang
  • , Yu Ren
  • , Wenhe Zhao
  • , Choo Chiap Chiau
  • , Qiang Li
  • , Liang Xu
  • , Jian Yue
  • , Ting Liang
  • , Lidan Jin
  • , Xiaoyu Fang
  • , Bohui Shi
  • , Zhiqiang Shi
  • , Peng Yuan
  • , Michael Gnant
  • Chinese Academy of Medical Sciences
  • Zhejiang University
  • Zunyi Medical University
  • LIANREN Digital Health
  • Shandong Cancer Hospital
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • Sir Run Run Shaw Hospital
  • Medical University of Vienna

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Objective: Neoadjuvant therapy (NAT) has become the standard treatment option for patients with locally advanced breast cancer. How to non-invasively screen out patients with pathological complete response (pCR) after NAT has become an urgent world-wide clinical problem. Our work aims to the assessment of neoadjuvant treatment response in breast cancer patients for higher accuracy prediction using innovative artificial intelligence system. Methods: In this study, we retrospectively collected longitudinal (pre-NAT and post-NAT) multi-parametric magnetic resonance imaging (MRI) and clinicopathologic data of a total of 1,315 breast cancer patients (clinical stage I−III) who had undergone NAT followed by standard surgery and treated across 5 independent medical centers from January 2010 to January 2023. We used radiomics, 3D convolutional neural network technology and clinical data statistical analysis methods to extract and screen multimodal features, and then developed and validated a Clinical-Radiomics-Deep-Learning (CRDL) model to predict patients’ pCR outcomes based on multimodal fusion features. Results: We use the area under the receiver operating characteristic curve (AUC) in the primary cohort (PC) and 3 external validation cohorts (VC1−3) to evaluate the model performance. The results showed that the AUC in the PC composed of 2 medical centers was 0.947 [95% confidence interval (95% CI): 0.931−0.960], and the AUC values in VC1−3 were 0.857 (95% CI: 0.810−0.901), 0.883 (95% CI: 0.841−0.918) and 0.904 (95% CI: 0.860−0.941), respectively. Conclusions: The CRDL model demonstrated high accuracy and robustness in predicting pCR to NAT using multimodal fusion data. This study provides a strong foundation for non-invasive assessment of pCR status in breast cancer patients following NAT and offers critical insights to guide clinical decision-making in post-NAT treatment planning.

Original languageEnglish
Pages (from-to)984-999
Number of pages16
JournalChinese Journal of Cancer Research
Volume37
Issue number6
DOIs
StatePublished - Dec 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Breast cancer
  • artificial intelligence
  • neoadjuvant therapy
  • pathological complete response
  • prediction model

Fingerprint

Dive into the research topics of 'A multicenter study of a predictive model for pathological complete response after neoadjuvant therapy in breast cancer using multimodal digital biomarkers'. Together they form a unique fingerprint.

Cite this